share_log

醫思健康：內幕消息銷售額更新

EC HEALTHCARE: INSIDE INFORMATION SALES VOLUME UPDATE

香港交易所 ·  Jan 23 18:45
Summary by Futu AI
醫思健康（EC Healthcare）於2024年1月23日發布公告，根據初步未經審計的管理帳目，2023年第四季度（10月1日至12月31日）的銷售額顯示正面增長。該季度整體銷售額預計不少於11億港元，同比增長超過7%。其中，醫療服務銷售額增長超過6%，香港及澳門的美學醫療、美容及養生服務銷售額增長超過5%，中國內地相關服務銷售額增長超過3%，而其他服務銷售額則錄得超過37%的增長。董事會提醒股東及潛在投資者，上述數據基於未經審核的管理賬目，並未經核數師審閱或審核，故最終財務表現可能受其他因素影響。投資者在買賣股份時應謹慎行事。
醫思健康（EC Healthcare）於2024年1月23日發布公告，根據初步未經審計的管理帳目，2023年第四季度（10月1日至12月31日）的銷售額顯示正面增長。該季度整體銷售額預計不少於11億港元，同比增長超過7%。其中，醫療服務銷售額增長超過6%，香港及澳門的美學醫療、美容及養生服務銷售額增長超過5%，中國內地相關服務銷售額增長超過3%，而其他服務銷售額則錄得超過37%的增長。董事會提醒股東及潛在投資者，上述數據基於未經審核的管理賬目，並未經核數師審閱或審核，故最終財務表現可能受其他因素影響。投資者在買賣股份時應謹慎行事。
EC Healthcare announced on 23 January 2024 that sales for the fourth quarter of 2023 (1 October to 31 December) showed positive growth in sales in the fourth quarter of 2023 (1 October to 31 December), based on preliminary unaudited management accounts. Overall sales for the quarter are expected to be at least HK$11 billion, up more than 7% year-on-year. Among them, sales of medical services grew by more than 6%, sales of aesthetic medical, beauty and health services in Hong Kong and Macau increased by more than 5%, sales of services related to Mainland China increased by more than 3%, and sales of other services increased by more than 37%. THE BOARD OF DIRECTORS REMINDS SHAREHOLDERS AND POTENTIAL INVESTORS THAT THE ABOVE DATA IS BASED ON UNAUDITED MANAGEMENT ACCOUNTS AND HAS NOT BEEN REVIEWED OR AUDITED BY AUDITORS AND THEREFORE THE FINAL FINANCIAL PERFORMANCE MAY BE AFFECTED BY OTHER FACTORS. Investors should exercise caution when buying and selling stocks.
EC Healthcare announced on 23 January 2024 that sales for the fourth quarter of 2023 (1 October to 31 December) showed positive growth in sales in the fourth quarter of 2023 (1 October to 31 December), based on preliminary unaudited management accounts. Overall sales for the quarter are expected to be at least HK$11 billion, up more than 7% year-on-year. Among them, sales of medical services grew by more than 6%, sales of aesthetic medical, beauty and health services in Hong Kong and Macau increased by more than 5%, sales of services related to Mainland China increased by more than 3%, and sales of other services increased by more than 37%. THE BOARD OF DIRECTORS REMINDS SHAREHOLDERS AND POTENTIAL INVESTORS THAT THE ABOVE DATA IS BASED ON UNAUDITED MANAGEMENT ACCOUNTS AND HAS NOT BEEN REVIEWED OR AUDITED BY AUDITORS AND THEREFORE THE FINAL FINANCIAL PERFORMANCE MAY BE AFFECTED BY OTHER FACTORS. Investors should exercise caution when buying and selling stocks.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.